# Block and Lock Strategy for Permanent HIV Latency

**ID:** CURE-009
**Year:** 2024
**Sources:**
- [Viruses Review (PMC11281696)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11281696/)
- [Frontiers Review (PMC7457024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7457024/)
- [Nature Communications 2025](https://www.nature.com/articles/s41467-025-59398-7)

---

## Abstract

The "block and lock" strategy represents an alternative approach to HIV cure that aims to permanently silence the integrated HIV provirus rather than eliminate it. Using latency-promoting agents (LPAs), this approach induces a state of deep, irreversible latency where the virus cannot reactivate, potentially enabling ART-free remission without complete viral eradication.

---

## Key Concepts

- **Block and Lock**: Inducing permanent transcriptional silencing of HIV provirus
- **Latency-Promoting Agents (LPAs)**: Small molecules that suppress HIV transcription
- **Deep Latency**: Enhanced state of transcriptional silence beyond normal latency
- **Functional Cure**: Sustained ART-free remission without complete eradication

---

## Comparison: Block and Lock vs Shock and Kill

| Feature | Shock and Kill | Block and Lock |
|:--------|:---------------|:---------------|
| Goal | Eliminate infected cells | Permanently silence provirus |
| Mechanism | Reactivate + immune clearance | Transcriptional repression |
| Provirus | Eliminated | Remains but silenced |
| Risk | Immune activation, toxicity | Unknown durability |
| Clinical trials | More advanced | Earlier stage |

---

## Key Latency-Promoting Agents

### 1. didehydro-Cortistatin A (dCA)
| Property | Description |
|:---------|:------------|
| Target | Tat TAR-binding domain |
| Mechanism | Blocks P-TEFb-mediated transcription |
| Effect | Reduces initiation and elongation |
| Evidence | Long-term treatment induces epigenetic silencing |

### 2. BRD4 Modulators (ZL0580)
| Property | Description |
|:---------|:------------|
| Target | Bromodomain 1 of BRD4 |
| Mechanism | Multiple pathways |
| Effects | Repressive chromatin at LTR; enhances BRD4-CDK9 binding |
| Combination | Synergistic with LEDGINs |

### 3. LEDGINs
| Property | Description |
|:---------|:------------|
| Target | LEDGF/p75-Integrase interaction |
| Mechanism | Retargets viral integration to silent chromatin |
| Effect | New proviruses integrate in transcriptionally inactive regions |
| Combination | Enhanced by BRD4 modulators |

---

## Recent Advances (2024-2025)

### BRD4 + LEDGIN Combination
A 2025 Nature Communications study showed:
- **ZL0580 + LEDGINs** achieve additive block-and-lock effect
- Combination silences HIV by:
  1. Retargeting integration to silent chromatin
  2. Blocking transcriptional enhancers
  3. Inducing repressive epigenetic marks

> "This offers a powerful combination strategy to block-and-lock HIV."

---

## Challenges and Considerations

### Scientific Challenges
| Challenge | Description |
|:----------|:------------|
| Durability | Unknown if silencing is truly permanent |
| Reactivation risk | Provirus remains and could potentially reactivate |
| Cell division | Silenced proviruses may still be transmitted to daughter cells |
| Specificity | Ensuring HIV-specific effects without cellular toxicity |

### Regulatory Pathway
> "Unlike latency reversal approaches, no block and lock strategy has been approved by the FDA. Therefore, clinical trials have lagged behind shock and kill approaches."

---

## Future Directions

### Combination Approaches
> "Whether the best aspects of both cure approaches can be combined—shock and kill cells that can be reactivated, then block and lock the remaining latent reservoir—is a combined approach that warrants future investigation."

### Clinical Translation
1. **Preclinical validation**: Continued animal model studies
2. **Safety assessment**: Long-term toxicity evaluation
3. **Biomarkers**: Developing measures of deep latency
4. **Human trials**: First-in-human studies anticipated

---

## Relevance to Project

Block and lock strategies inform the Ternary VAE project:
- **LTR sequences**: Promoter variants affecting silencing susceptibility
- **Tat mutations**: Variants affecting dCA binding and function
- **Epigenetic determinants**: Sequence features associated with silencing
- **Integration sites**: Predicting transcriptionally silent regions

---

*Added: 2025-12-24*
